Innovative Therapeutics HC Bioscience specializes in pioneering tRNA-based therapeutics targeting genetically defined diseases, presenting an opportunity to collaborate with advanced biotech firms or healthcare providers seeking novel treatment options.
Growing Leadership Recent strategic hires of senior executives in business development, finance, and scientific leadership indicate the company's expanding operational capacity, making them a prime candidate for partnership or investment opportunities.
Pipeline Advancements With promising preclinical data in Duchenne muscular dystrophy and hemophilia A, HC Bioscience is on the cusp of future clinical development stages, creating potential for sales of specialized research tools, platforms, or services supporting their pipeline.
Funding & Market Position Having secured $16 million in funding and maintaining a revenue range of $1M to $10M, HC Bioscience is positioned for growth, representing opportunities for financial services, strategic alliances, and early-stage collaborative funding.
Research Focus & Partnerships Their focus on precision medicine and genetic therapies aligns with a broader market trend toward personalized healthcare, making them a potential partner for technology providers, contract research organizations, or academic collaborations.
$1B$10B
$1B$10B
$1B$10B
$10B
$1B$10B
$1B$10B
$1B$10B
$10B
$1B$10B
$10BHC Bioscience, Inc. uses 8 technology products and services including RSS, MySQL, Font Awesome, and more. Explore HC Bioscience, Inc.'s tech stack below.
| HC Bioscience, Inc. Email Formats | Percentage |
| First.Last@hcbioscience.com | 49% |
| First@hcbioscience.com | 1% |
| First.Last@hcbioscience.com | 49% |
| First@hcbioscience.com | 1% |
Biotechnology ResearchMassachusetts, United States2-10 Employees
HC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics targeting protein dysfunction. HC’s innovations in precision protein editing therapies target genetically defined diseases. A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.
Company Overview
Media & News
Funding & FinancialsHC Bioscience, Inc. has raised a total of $16M of funding over 2 rounds. Their latest funding round was raised on Nov 04, 2022 in the amount of $16M.
HC Bioscience, Inc.'s revenue is estimated to be in the range of $1M$10M
Funding & FinancialsHC Bioscience, Inc. has raised a total of $16M of funding over 2 rounds. Their latest funding round was raised on Nov 04, 2022 in the amount of $16M.
HC Bioscience, Inc.'s revenue is estimated to be in the range of $1M$10M
1-888-653-2347 
support@leadiq.com